Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 141 clinical trials
featured
Do you miss that loving feeling? A hysterectomy can affect your sexual desire.

Do you miss that loving feeling? A hysterectomy can affect your sexual desire.

  • 270 views
  • 08 Nov, 2020
  • 1 location
featured
RTOG 1115: Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate Cancer

RTOG 1115: Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate Cancer

  • 74 views
  • 08 Nov, 2020
  • 1 location
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. PURPOSE: This randomized phase III

antiandrogens
epinephrine
androgen suppression
antiandrogen therapy
androgens
  • 401 views
  • 07 Nov, 2020
  • 9 locations
Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer

RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy, such as cyproterone acetate may stop the adrenal glands from making androgens. Sometimes the tumor may

tumor progression
endocrine therapy
gonadotropin
epinephrine
gonadorelin
  • 3 views
  • 07 Nov, 2020
  • 1 location
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

has spread to other places in the body. Androgens can cause the growth of prostate cancer cells. Antiandrogen therapy may lessen the amount of androgens made by the body. Drugs used in chemotherapy

  • 22 views
  • 18 Apr, 2021
  • 15 locations
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus ADT in participants with mHSPC. The primary hypothesis is that in participants with mHSPC, the combination of pembrolizumab plus enzalutamide plus ADT is superior to placebo plus enzalutamide plus ADT with …

  • 272 views
  • 14 Jun, 2021
  • 223 locations
Simvastatin and Metformin Therapy in PCOS Women. Prospective Randomised Trial.

The purpose of this study is to compare effects of statins (simvastatin) and metformin on clinical (menstrual cycle, excessive hair, skin problems), endocrine (androgens), metabolic

cushing's syndrome
prolactin
metformin
acne
testosterone
  • 100 views
  • 07 Nov, 2020
  • 1 location
Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial

regimens like the use of growth hormones, DHEA or androgens to improve the outcomes (Kyrou D, et al, 2009). The main interest of this study is the use of myo-inositol prior to IVF cycles for improvement of

  • 0 views
  • 23 Jan, 2021
  • 1 location
Low-Dose Danazol for the Treatment of Telomere Related Diseases

Background DNA is a structure in the body. It contains data about how the body develops and works. Telomeres are found on the end of chromosomes in DNA. Some people with short telomeres or other gene changes can develop diseases of the bone marrow, lung, and liver. Researchers want to …

  • 57 views
  • 08 Apr, 2021
  • 1 location
Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate

The main objective of this study is to evaluate the response of erectile dysfunction in hypogonadotrophic males with Testosterone undecanoate i.m. as per IIEF and the question of the GAQ (Global Evaluation Questionnaire) after 42 weeks of treatment. Secondary Study Objectives - To monitor adverse events and changes in hemoglobin …

testosterone
hypogonadism
  • 209 views
  • 07 Nov, 2020
  • 2 locations